Digital Health Investment
Curenta Series Seed Round

 Target Annual Return

MOIC: 5.6× by 2029

Target Term

4-7 Years

Close Date

Q3 2025

Tax Treatment

K-1 pass-through reporting

Status

Active

Remaining

75%

Invest now

Minimum Commitment: $25,000
Accepting $25,000 – $2,000,000 investments

Mission & Vision

Curenta’s mission is to redefine long-term care operations by building the first autonomous workforce for Assisted Living Facilities (ALFs). The company envisions a future where AI agents handle the administrative and compliance burden, allowing caregivers to focus solely on human care. Curenta aims to become the dominant operating system for senior care, ultimately expanding across the broader long-term care spectrum including skilled nursing, home health, and hospice. The ambition is not just software efficiency, but transformative impact on labor cost, compliance outcomes, and care quality.

Product

Curenta is an AI-native EMR platform designed specifically for ALFs. The platform includes a suite of intelligent agents: the AI Med Manager, AI Note Taker, AI Task Manager, and AI Compliance Agent. These agents work together to orchestrate care delivery, document services in real time, ensure compliance, and reduce the need for manual data entry. The product addresses three critical pain points for ALFs:
  1. Labor Intensity – High staff turnover (60-80%) and significant time spent on documentation.
  2. Compliance Risk – Costly citations from inconsistent recordkeeping.
  3. Administrative Inefficiency – Manual workflows that burden already-stretched staff.
Unlike legacy EMRs that only document care, Curenta automates and executes it. The platform integrates state-specific regulations and provides proactive prompts to staff. The result is improved compliance, reduced admin costs, and better outcomes.

Market

Curenta is addressing a large and growing opportunity in long-term care. The immediate Serviceable Available Market (SAM) consists of the U.S. Assisted Living Facility (ALF) segment, which includes over 1.2 million beds. If Curenta were deployed across all ALFs at its current pricing, the total addressable revenue would be approximately $1.73B annually—this is the basis of the figure cited in external materials. Importantly, this estimate does not include adjacent verticals like Skilled Nursing Facilities (SNFs) and hospice, which represent significant future upside.

The ALF market alone is growing at an 8.3% CAGR through 2031, driven by demographic shifts and increased regulatory pressure. SNFs and hospice add thousands of additional facilities and operators, with similar documentation, staffing, and compliance challenges. These are natural adjacencies for Curenta’s product expansion.

The timing is strong: facilities are under pressure to increase quality while reducing reliance on scarce human labor. AI-native infrastructure is poised to become table stakes in care delivery, and Curenta’s early mover advantage gives it the opportunity to become the category standard.

Team

The team is composed of experienced operators with deep vertical expertise:

  • Ramy Barsoum (CEO) – Serial healthcare entrepreneur. Built and exited a SoCal LTC pharmacy chain; scaled AllRx to $10M revenue and $1.5M EBITDA with just $1.8M raised.
  • Shona Herbert (VP Sales) – 20+ years in healthcare sales; previously led sales at WellSky, the largest EMR in home health.
  • Peter Tran (Product Manager) – PharmD with over a decade in LTC pharmacy and product.
  • Usama Atteya (Director of Engineering) – 11+ years in full-stack development, cloud architecture, AI, and DevOps.

The founder-market fit is unusually strong. Ramy has personally operated in the industry and built two successful businesses in it. This is a team of insiders solving insider problems with insider knowledge.

Business Model

Curenta operates a SaaS model with per-bed monthly pricing. The platform is sold in tiers based on the number of AI agents activated:

  • Starter (2 agents): $15/bed/month
  • Professional (8 agents): $20/bed/month
  • Elite (13 agents): $25/bed/month

Facilities pay annual contracts with a 10-bed minimum. For a 50-bed facility, pricing ranges from $9K to $15K annually. However, many facilities are significantly larger: 100 to 1,000+ beds. At this scale, individual contract values can range from $30K to over $250K annually, creating the opportunity for high ACVs and multi-site expansion.

The company benefits from strong upsell dynamics as customers expand AI agent usage.

Early Traction:

  • 32 facilities as of April 2025
  • $157K ARR and projected $591K ARR by December 2025
  • CAC dropping MoM; payback period under 6 months
  • Short sales cycle (~2 months)

Use of Funds Relevance: Curenta’s next stage of growth hinges on building an enterprise-grade sales motion. Selling into larger operators and multi-site chains requires longer cycles, deeper solution engineering, and C-suite alignment. Funding will support the talent and infrastructure required to win and scale within these high-value accounts.

Competitive Landscape

The market is fragmented with outdated legacy players like Yardi, Eldermark, and PCC, which rely on manual workflows. Newer platforms like August Health and Alis offer marginal automation but are still documentation-first.

Curenta is the first to:

  • Execute tasks vs. just recording them
  • Embed AI agents into core workflows
  • Offer compliance-native automation

The team’s deep knowledge of state-level compliance and AI orchestration positions Curenta as a category-defining platform. Competitors either lack vertical depth or technical sophistication.

Key Risks

  1. Sales Execution – Selling into fragmented, relationship-driven ALFs can be slow and uneven. Mitigation: Building an enterprise sales motion, leveraging channel partners, and deploying a land-and-expand strategy to drive multi-site growth.
  2. Technical Debt – Expanding the AI stack and compliance logic could increase complexity and slow iteration. Mitigation: Modular architecture, decoupled compliance engine, and strong CI/CD practices ensure scalability.

3. Regulatory Evolution – Changing state-level regulations may require ongoing product updates. Mitigation: A dynamic rules engine, in-house compliance expertise, and external advisory relationships enable rapid adaptation.
Why It’s Worth It: The team has already navigated these dynamics before. Early traction and fast iteration cycles point to strong product-market fit and operational resilience.

Exit Potential

Potential acquirers include:

  • Strategics: PointClickCare, Yardi, MatrixCare, WellSky
  • Private Equity rollups: Vista, Thoma Bravo, Welsh Carson (all active in LTC software)

Comparable exits in the space (e.g. MatrixCare, Brightree) occurred at 8–12x revenue. If Curenta reaches its $30M ARR goal by 2030, a conservative 5x exit implies $150M+ enterprise value. With a $21M post-money valuation today, this implies 7x+ MOIC potential.

Conclusion

Curenta is a rare combination of AI-native product, insider team, and huge pain point in a massive, growing market. The timing aligns with labor-driven cost pressure and the healthcare sector’s rapid adoption of automation. This is a team that knows where the bodies are buried and is automating the most expensive parts of care.

Why now: Labor shortages and compliance pressure have reached a breaking point.

Why us: We understand vertical SaaS, healthcare distribution, and can help scale fundraising and enterprise partnerships.

Why this team: They’ve built and sold in this space before. They’re not learning the industry—they’re rebuilding it.

Curenta is not just the next EMR. It’s the first autonomous workforce for long-term care—and that’s a category worth owning.

Documents

Financing Memo - PDF

View
Download

Financial/Market Model - PDF

View
Download

Deal Summary

Curenta is raising a $4.0M Seed round to scale its AI-driven EMR platform and accelerate customer acquisition. The round is led by InVitro Capital with $2.2M already committed. The company is valued at $17M pre-money, reflecting meaningful traction in product development, commercial pilots, and team strength.

Round Type

Seed

Total Round Size

$4.0M

Amount Committed to Date

$2.2M

Pre-Money Valuation

$17.0M

Post-Money Valuation (fully subscribed)

$21.0M

Security Type

Preferred Equity

Effective Share Price

$1.41

New Shares Issued (at full raise)

2,845,249

Post-Money Shares Outstanding

14,937,557

Lead Investor

InVitro Capital
Invest now